Edwin de Graaf
Directeur Général chez Gilde Healthcare Partners BV
Profil
Edwin William de Graaf founded Gilde Healthcare Partners BV in 2006, where he is working as Managing Partner from 2006.
Mr. de Graaf also currently works at Gilde Healthcare Holding BV, as Co-Managing Director, Sanifit Therapeutics SA, as Director, Tagworks Pharmaceuticals BV, as Director, and AM-Pharma Holding BV, as Member-Supervisory Board.
Mr. de Graaf also formerly worked at Gilde Investment Management BV, as Investment Director from 1998 to 2006, Roche Innovation Center Copenhagen A, as Director, Amsterdam Molecular Therapeutics (AMT) Holding NV, as Director, Prosonix Ltd., as Non-Executive Director, Ascendis Pharma A, as Director, Pieris AG, as Member-Supervisory Board, AM-Pharma BV, as Member-Supervisory Board, and uniQure NV, as Member-Supervisory Board.
Mr. de Graaf received his graduate degree from Erasmus University Rotterdam.
Postes actifs de Edwin de Graaf
Sociétés | Poste | Début |
---|---|---|
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Directeur Général | 01/07/2006 |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Directeur/Membre du Conseil | - |
Gilde Healthcare Holding BV
Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Directeur Général | - |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Directeur/Membre du Conseil | - |
Tagworks Pharmaceuticals BV
Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Directeur/Membre du Conseil | - |
Anciens postes connus de Edwin de Graaf
Sociétés | Poste | Fin |
---|---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Directeur/Membre du Conseil | 02/09/2014 |
UNIQURE N.V. | Directeur/Membre du Conseil | 08/11/2013 |
Gilde Investment Management BV
Gilde Investment Management BV Investment ManagersFinance Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht. | Private Equity Investor | 01/07/2006 |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Directeur/Membre du Conseil | - |
░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Edwin de Graaf
Erasmus University Rotterdam | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
UNIQURE N.V. | Health Technology |
ASCENDIS PHARMA A/S | Health Technology |
Entreprise privées | 11 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Pieris AG
Pieris AG BiotechnologyHealth Technology Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany. | Health Technology |
Prosonix Ltd.
Prosonix Ltd. Pharmaceuticals: MajorHealth Technology Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Gilde Investment Management BV
Gilde Investment Management BV Investment ManagersFinance Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht. | Finance |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Finance |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Gilde Healthcare Holding BV
Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Finance |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
Tagworks Pharmaceuticals BV
Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Health Technology |